Skip to content
Medical Health Aged Care, Women

Landmark gathering to hear of promising uptake on cervical cancer screening

Public Health Association of Australia 2 mins read

Media alert

1 August 2023

Preliminary results from one of Australia’s largest randomised controlled trials suggest that HPV-based screening used in the National Cervical Cancer Screening Program is more effective at detecting pre-cancerous changes than the Pap Smear program it replaced.

If the early results from the Compass Trial are confirmed when it concludes in 2026, this would allow more women and people with a cervix to be treated before these changes develop into cervical cancer, alleviating for many people the trauma of a cancer diagnosis, and ultimately saving more lives.

The update, from the Australian Centre for the Prevention of Cervical Cancer and the Daffodil Centre, will be shared with 150 Australian and international screening experts, researchers, and policymakers today in Melbourne at Cancer Screening: Evidence, challenges and solutions, organised by the Public Health Association of Australia (PHAA). Sessions will cover cancers including lung, breast, and melanoma and skin cancer.

The cancer screening symposium is the first of its kind to be convened on the continent. Delegates will discuss the latest evidence and initiatives to promote early cancer detection, and whether there is evidence to support changes to screening programs, or the introduction of new screening technologies.

The symposium’s international keynote speaker is Prof Bob Steele CBE, who led the United Kingdom’s demonstration pilot that was used to inform the decision to introduce national bowel cancer screening programmes throughout the UK. The Professor of Surgery at the University of Dundee is the Clinical Director of the Scottish Bowel Cancer Screening Programme. Prof Steele was also the Chair of UK National Screening Committee for six years until 2022, and has significant expertise in screening evidence, emerging screening technologies, and the latest proposals.

The event agenda includes discussions on: 

  • Cancer screening – where to next in Australia and the UK?
  • When equity is the goal – initiatives to ensure screening programs activity address outcome disparities 
  • Building timely evidence for screening program changes and new technologies
  • “Are we ready for the future?”

Media are invited to attend online or in-person, and request interviews with presenters.

 

WHO: Public Health Association of Australia

WHAT: Screening Symposium. Cancer Screening: Evidence, challenges, and solutions

WHERE: Melbourne Convention Exhibition Centre, (Clarendon Foyer and Auditorium)

WHEN: 9am – 5:15pm, Tuesday 1 August 2023

 

For further information/comment:

Paris Lord (he/him), PHAA Communications and Media Manager, M) 0478 587 917 / [email protected]

A/Prof Misha Coleman, Government Relations and Communications Director,
Australian Centre for the Prevention of Cervical Cancer, M) 0428 399 739,
[email protected]


Contact details:

Paris Lord (he/him), PHAA Communications and Media Manager, M) 0478 587 917 / [email protected]

A/Prof Misha Coleman, Government Relations and Communications Director,
Australian Centre for the Prevention of Cervical Cancer, M) 0428 399 739,
[email protected]

Media

More from this category

  • Medical Health Aged Care
  • 09/12/2025
  • 05:30
Centre for Eye Research Australia

Australian scientists reveal new genetic risk for severe macular degeneration

Researchers and a person living with macular degeneration are available for interview in East Melbourne today. Australian researchers have for the first time pinpointed specific genetic changes that increase the risk of severe, sight-threatening forms of age-related macular degeneration (AMD). A new study, published today inNature Communications, reveals the specific genetic factors linked to the presence of reticular pseudodrusen - deposits which drive vision loss and are found on the retina of up to 60 per cent of people with advanced AMD. The research, led by the Centre for Eye Research Australia, WEHI and the University of Melbourne, offers a…

  • Medical Health Aged Care
  • 09/12/2025
  • 01:11
SoluPet Inc.

SoluPet Inc. (SoluPet) Announces Strategic Partnership with CHC Healthcare Group (CHC) to Advance Canine Cognitive Health in Asia

Partnership with CHC in Taiwan will pilot SoluPet’s flagship Neuronal Defense™ formulation through CHC’s veterinary and consumer-health ecosystem TORONTO–BUSINESS WIRE– SoluPet,the data and science-driven…

  • Contains:
  • Medical Health Aged Care
  • 09/12/2025
  • 00:11
AdvanCell

AdvanCell Receives First Delivery of High-Activity Thorium-228, Highlighting a Unique Industry Capability and Expertise Essential to Scaling Lead-212 Production for Targeted Alpha Therapies

Thorium-228 (228Th) is the parent isotope and key starting material to produce the alpha-emitter Lead-212 (212Pb) The established capability to receive and process high-activity…

  • Contains:

Media Outreach made fast, easy, simple.

Feature your press release on Medianet's News Hub every time you distribute with Medianet. Pay per release or save with a subscription.